Skip to main content

Drug Interactions between gemfibrozil and iptacopan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

gemfibrozil iptacopan

Applies to: gemfibrozil and iptacopan

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2C8 may significantly increase the plasma concentrations and the risk of adverse effects associated with iptacopan, which is primarily metabolized by the isoenzyme. Increased systemic exposure to iptacopan may result in an increased risk of adverse effects including potentially serious and life-threatening bacterial infections, abdominal pain, diarrhea, headache, hyperlipidemia, nasopharyngitis, nausea, rash, thrombocytopenia, and viral infection. Clinical data evaluating this interaction are not available.

MANAGEMENT: The concomitant administration of potent CYP450 2C8 inhibitors with iptacopan should generally be avoided.

References (3)
  1. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals Australia Pty Ltd
  2. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals, SUPPL-1
  3. Novartis Pharmaceuticals Canada Inc Product Monograph. Fabhalta (iptacopan) https://pdf.hres.ca/dpd_pm/00078186.PDF

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer